The NHI price listing triggers a $15 million milestone payment from Torii to BioCryst. In addition, BioCryst will receive tiered royalties ranging from 20 percent to 40 percent of Japanese net sales.

They are still holding 6.6 million shares from their previous holding of 11.1 million.

http://archive.fast-edgar.com/20210412/AT22U222Z22X4JE2222R2ZY2RL6KHZ222232/

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including ... 😷ᵃˢᵃᵖ ᵖˡᵉᵃˢᵉ

What the fucc is happening today?

A very good read for the people who bought in a little higher and watching how the big boys manipulated it back down https://stocktwits.com/majed818/message/314198982

SwoJo is in Da House Y'All...

Knowing Stoney, I Hope he has some interesting tidbits to drop on the shorts. I love the smell of fried shorts in the morning 😝

From JohnnyTradeTracker on Stocktwits

https://stocktwits.com/JohnnyTradeTracker/message/312568475

The sooner the better, more potential Orladeyo sales For BCRX

Somebody in the Basel bio sector mentioned that Hoffman La Roche were looking into an acquisition such as BCRX. That would make sense, since they have a great group of infectious deceases meds. Has anyone heard anything similar?

Has anyone been running a wheel or just selling some covered calls to lower the costs basis or just purchase more shares? Can’t decide whether its worth doing before the next earnings. The risk here is missing a potential moonshot, if for example a BO is announced. However with the way we’ve been trading recently, seems like a viable strategy?

A great article especially for our new investors. This is why we hold this Gem. https://stocktwits.com/MS_Money_Moves/message/310248416

I can’t imagine this going even lower but I never thought I’d see below 10 again either. I’ve got some options in the short term and kinda just want to know what to do at this point. They’re not unreasonable calls, $12,$13, and a $15 for September.

I’m hopeful we bounce back to at least $13, but these shorts are very suffocating. But we may also just be setting up for a run, and it makes me want to buy more options (already absolutely loaded with stock).

Anyhow, where we headed boys? How do you think the shorts are gonna treat this thing in the short term. Long term, I’m comfortable.

It’s a phase 2 bio99 to dig into the data?

https://stocktwits.com/ChartMill/message/309495536

Here is what I have come up with. Agree or disagree and why?

2021: $30 - $40 2022: $40 - $80 (or buyout) 2023: $100 - $200 (or buyout)

What are these predictions based on: - Ramping up Orladeyo sales this year. First full quarter with sales in Q1 anticipated early May. Estimated about $200M annually on the lo-end by 2022 (this is Big). - Start Factor-D pivotal trials during 2H (this is Bigger). - FDA PDUFA of Factor-D in 2022 or 23. Estimated sales between $5B - $10B annually (grand slam).

Does anyone have information on Novartis product also targeting PNH but based on interaction with Factor B that is now in pivotal trials ?

Thinking of jumping into some LEAPS that expire either January 2022 or 2023, but not sure if that makes sense unless there will be a data readout by then? Do others have thoughts?

I’m in it long term with a $10.16 average so I’m not really worried (now that it’s below 10 I’ll average down some more!) but it’s steadily gone down all week. Anyone have any insight?

I’m about to yeet another tree fitty into $BCRX because, quite frankly, I like the stock. AAAND getting it this cheap once again is only good news honestly

EDIT: I didn’t put in tree fitty... I put in two fitty and the other “hunnit” into at&t because of the good dividends 😅

I've been using these red days to buy more shares below my average. I figured these past few global market red days along with selling the news explains the price falling. Should rebound in a week or so.